193 related articles for article (PubMed ID: 31298164)
21. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
Canestaro WJ; Austin MA; Thummel KE
Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
[TBL] [Abstract][Full Text] [Related]
22. Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury.
Jin S; Li X; Fan Y; Fan X; Dai Y; Lin H; Cai W; Yang J; Xiang X
Basic Clin Pharmacol Toxicol; 2019 Dec; 125(6):508-517. PubMed ID: 31240859
[TBL] [Abstract][Full Text] [Related]
23. SLCO1B1 Gene Polymorphisms (rs2306283 and rs4149056) and Statin-Induced Myopathy in Jordanian Diabetics.
Shahrure ZM; Irshaid YM; Mustafa KN; Abujbara MA; Al Shhab M; El-Khateeb MS; Ajlouni KM
Curr Rev Clin Exp Pharmacol; 2021; 16(3):281-288. PubMed ID: 32860365
[TBL] [Abstract][Full Text] [Related]
24. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Xiang Q; Chen SQ; Ma LY; Hu K; Zhang Z; Mu GY; Xie QF; Zhang XD; Cui YM
Pharmacogenomics J; 2018 Dec; 18(6):721-729. PubMed ID: 30250148
[TBL] [Abstract][Full Text] [Related]
25. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.
Jiang F; Choi JY; Lee JH; Ryu S; Park ZW; Lee JG; Na HS; Lee SY; Oh WY; Chung MW; Choi SE
Pharmacogenomics; 2017 Apr; 18(5):459-469. PubMed ID: 28350522
[TBL] [Abstract][Full Text] [Related]
26. Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.
Carr DF; Francis B; Jorgensen AL; Zhang E; Chinoy H; Heckbert SR; Bis JC; Brody JA; Floyd JS; Psaty BM; Molokhia M; Lapeyre-Mestre M; Conforti A; Alfirevic A; van Staa T; Pirmohamed M
Clin Pharmacol Ther; 2019 Dec; 106(6):1353-1361. PubMed ID: 31220337
[TBL] [Abstract][Full Text] [Related]
27. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study.
Mirošević Skvrce N; Macolić Šarinić V; Šimić I; Ganoci L; Muačević Katanec D; Božina N
Pharmacogenomics; 2015 Jul; 16(8):803-15. PubMed ID: 26086347
[TBL] [Abstract][Full Text] [Related]
28. The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.
León-Cachón RBR; Bamford AD; Meester I; Barrera-Saldaña HA; Gómez-Silva M; Bustos MFG
Sci Rep; 2020 Jun; 10(1):8900. PubMed ID: 32483134
[TBL] [Abstract][Full Text] [Related]
29. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
30. Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report.
Kiage J; Venkatanarayan A; Roth M; Elam M
J Clin Lipidol; 2022; 16(1):23-27. PubMed ID: 34887219
[TBL] [Abstract][Full Text] [Related]
31. Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients.
Mei Y; Wang SY; Li Y; Yi SQ; Wang CY; Yang M; Duan KM
J Clin Pharmacol; 2015 Mar; 55(3):261-8. PubMed ID: 25279974
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of dyslipidemia and gene polymorphisms of ABCB1 and SLCO1B1 in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe populations with coronary heart disease in Xinjiang, China.
Wang T; Sun L; Xu L; Zhao T; Feng J; Yu L; Wu J; Li H
Lipids Health Dis; 2021 Sep; 20(1):116. PubMed ID: 34563206
[TBL] [Abstract][Full Text] [Related]
33. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
34. The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence.
Li X; Sun S; Xu X; Zhao Z; Li W
Drug Res (Stuttg); 2019 Apr; 69(4):185-193. PubMed ID: 30193394
[TBL] [Abstract][Full Text] [Related]
35. The frequency of major
Alrajeh K; AlAzzeh O; Roman Y
Pharmacogenomics; 2023 May; 24(7):381-398. PubMed ID: 37222158
[TBL] [Abstract][Full Text] [Related]
36. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
[TBL] [Abstract][Full Text] [Related]
37. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.
Vandell AG; Lee J; Shi M; Rubets I; Brown KS; Walker JR
Pharmacogenomics J; 2018 Jan; 18(1):153-159. PubMed ID: 27897269
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of protective haplotypes of the
Favela-Mendoza AF; Rodríguez-Rodríguez BG; Rojas-Prado E; Chávez-Arreguin M; Aguilar-Velázquez JA; Martínez-Cortés G; Rangel-Villalobos H
Per Med; 2021 Sep; 18(6):533-540. PubMed ID: 34674552
[TBL] [Abstract][Full Text] [Related]
39. Influence of
Mladenovska K; Grapci AD; Vavlukis M; Kapedanovska A; Eftimov A; Geshkovska NM; Nebija D; Dimovski AJ
Pharmazie; 2017 May; 72(5):288-295. PubMed ID: 29441875
[TBL] [Abstract][Full Text] [Related]
40. Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.
Ahern TP; Damkier P; Feddersen S; Kjærsgaard A; Lash TL; Hamilton-Dutoit S; Lythjohan CB; Ejlertsen B; Christiansen PM; Cronin-Fenton DP
Acta Oncol; 2020 Sep; 59(9):1009-1015. PubMed ID: 32351149
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
